arrow_back Trending Legislation
Share share

Increased Transparency for 340B Drug Discount Program

New rules enhance oversight of the 340B drug discount program, requiring healthcare facilities to report how they use savings from drug purchases. This aims to ensure that discounts genuinely benefit patients, especially those with limited means, and to increase public access to information about the program.
Key points
Healthcare facilities must report how they use savings from discounted drug purchases, ensuring funds benefit patients.
Information on discount usage will be publicly available, allowing citizens to see how facilities manage funds.
Financial penalties are introduced for non-compliance with new reporting rules, aiming for greater program discipline and transparency.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
340B Transparency Act
Print number: HR 3290
Sponsor: Rep. Bucshon, Larry [R-IN-8]
Process start date: 2023-05-15
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Increased Transparency for 340B Drug Discount Program

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 3290.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-05-15.

What are the main provisions?

Key points include:

  • Healthcare facilities must report how they use savings from discounted drug purchases, ensuring funds benefit patients.
  • Information on discount usage will be publicly available, allowing citizens to see how facilities manage funds.
  • Financial penalties are introduced for non-compliance with new reporting rules, aiming for greater program discipline and transparency.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Bucshon, Larry [R-IN-8].

What is the latest detailed status?

The latest detailed status is: Placed on the Union Calendar, Calendar No. 628.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Analysis and Potential Impact of HR 3290

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health